199 related articles for article (PubMed ID: 28146264)
21. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.
Yang JJ; Landier W; Yang W; Liu C; Hageman L; Cheng C; Pei D; Chen Y; Crews KR; Kornegay N; Wong FL; Evans WE; Pui CH; Bhatia S; Relling MV
J Clin Oncol; 2015 Apr; 33(11):1235-42. PubMed ID: 25624441
[TBL] [Abstract][Full Text] [Related]
22. [Significance of NUDT15 gene in individualized treatment with 6-mercaptopurine in children with acute lymphoblastic leukemia].
He J; Liu L
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Jan; 21(1):100-104. PubMed ID: 30675872
[TBL] [Abstract][Full Text] [Related]
23. Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia.
Naushad SM; Dorababu P; Rupasree Y; Pavani A; Raghunadharao D; Hussain T; Alrokayan SA; Kutala VK
Cancer Chemother Pharmacol; 2019 May; 83(5):875-880. PubMed ID: 30806759
[TBL] [Abstract][Full Text] [Related]
24. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity.
Moriyama T; Nishii R; Perez-Andreu V; Yang W; Klussmann FA; Zhao X; Lin TN; Hoshitsuki K; Nersting J; Kihira K; Hofmann U; Komada Y; Kato M; McCorkle R; Li L; Koh K; Najera CR; Kham SK; Isobe T; Chen Z; Chiew EK; Bhojwani D; Jeffries C; Lu Y; Schwab M; Inaba H; Pui CH; Relling MV; Manabe A; Hori H; Schmiegelow K; Yeoh AE; Evans WE; Yang JJ
Nat Genet; 2016 Apr; 48(4):367-73. PubMed ID: 26878724
[TBL] [Abstract][Full Text] [Related]
25. DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.
Ju HY; Lee JW; Cho HW; Hyun JK; Ma Y; Yi ES; Yoo KH; Sung KW; Choi R; Koo HH; Lee SY
PLoS One; 2021; 16(1):e0245667. PubMed ID: 33481917
[TBL] [Abstract][Full Text] [Related]
26. Mercaptopurine induced myelosuppression in a child with a
Gupta N; Magatha LS; Jayaraman D; Scott JX; Antony SB; Koshy T
J Oncol Pharm Pract; 2023 Jun; 29(4):999-1001. PubMed ID: 36341754
[TBL] [Abstract][Full Text] [Related]
27. Low NUDT15 expression levels due to biallelic NUDT15 variants and 6-mercaptopurine intolerance.
Yoshida M; Brown SA; Moriyama T; Nishii R; Tsujimoto SI; Yamada Y; Yoshida K; Shirai R; Osumi T; Utano T; Fukano R; Kudo K; Sakaguchi K; Arakawa Y; Koh K; Sekiguchi M; Sekimizu M; Miyamura T; Ishida H; Inukai T; Tomizawa D; Kiyokawa N; Kato M; Yang JJ
Br J Haematol; 2022 Oct; 199(2):270-276. PubMed ID: 35905175
[TBL] [Abstract][Full Text] [Related]
28. Determination of NUDT15 variants by targeted sequencing can identify compound heterozygosity in pediatric acute lymphoblastic leukemia patients.
Yu CH; Chang YH; Wang DS; Jou ST; Lin CY; Lin KH; Lu MY; Raghav L; Chang HH; Wu KH; Chou SW; Ni YL; Lin DT; Lin SW; Chen HY; Yang YL
Sci Rep; 2020 Sep; 10(1):14400. PubMed ID: 32873882
[TBL] [Abstract][Full Text] [Related]
29.
Puangpetch A; Tiyasirichokchai R; Pakakasama S; Wiwattanakul S; Anurathapan U; Hongeng S; Sukasem C
Pharmacogenomics; 2020 Apr; 21(6):403-410. PubMed ID: 32308129
[No Abstract] [Full Text] [Related]
30. Influence of age, sex, and haplotypes of thiopurine methyltransferase (TPMT) gene on 6- mercaptopurine toxicity in children with acute lymphoblastic leukemia.
Uppugunduri CR; Ansari M
Eur J Clin Pharmacol; 2012 May; 68(5):887-8; author reply 885-6. PubMed ID: 22166935
[No Abstract] [Full Text] [Related]
31. Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia.
Tanaka Y; Urayama KY; Mori M; Arakawa Y; Hasegawa D; Noguchi Y; Yanagimachi M; Keino D; Ota S; Akahane K; Inukai T; Hangai M; Kawaguchi T; Takagi M; Koh K; Matsuda F; Manabe A
Br J Haematol; 2022 Oct; 199(2):260-269. PubMed ID: 35961941
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.
Tanaka Y; Kato M; Hasegawa D; Urayama KY; Nakadate H; Kondoh K; Nakamura K; Koh K; Komiyama T; Manabe A
Br J Haematol; 2015 Oct; 171(1):109-15. PubMed ID: 26033531
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetic evaluation of 6-mercaptopurine-mediated toxicity in pediatric acute lymphoblastic leukemia patients from a South Indian population.
Ramalingam R; Kaur H; Scott JX; Sneha LM; Arun Kumar GP; Srinivasan A; Paul SF
Pharmacogenomics; 2021 May; 22(7):401-411. PubMed ID: 33876659
[No Abstract] [Full Text] [Related]
34. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Stocco G; Crews KR; Evans WE
Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
[TBL] [Abstract][Full Text] [Related]
35. An international retrospective study for tolerability of 6-mercaptopurine on NUDT15 bi-allelic variants in children with acute lymphoblastic leukemia.
Tanaka Y; Yeoh AEJ; Moriyama T; Li CK; Kudo K; Arakawa Y; Buaboonnam J; Zhang H; Liu HC; Ariffin H; Chen Z; Kham SKY; Nishii R; Hasegawa D; Fujimura J; Keino D; Kondoh K; Sato A; Ueda T; Yamamoto M; Taneyama Y; Hino M; Takagi M; Ohara A; Ito E; Koh K; Hori H; Manabe A; Yang JJ; Kato M
Haematologica; 2021 Jul; 106(7):2026-2029. PubMed ID: 33504140
[No Abstract] [Full Text] [Related]
36. Susceptibility to thiopurine toxicity by
Correa-Jimenez O; Yunis JJ; Linares-Ballesteros A; Sarmiento-Urbina I
Colomb Med (Cali); 2021; 52(3):e2074569. PubMed ID: 35431360
[TBL] [Abstract][Full Text] [Related]
37. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry.
Schaeffeler E; Jaeger SU; Klumpp V; Yang JJ; Igel S; Hinze L; Stanulla M; Schwab M
Genet Med; 2019 Sep; 21(9):2145-2150. PubMed ID: 30728528
[TBL] [Abstract][Full Text] [Related]
38. Association of
Kodidela S; Dorababu P; Thakkar DN; Dubashi B; Sundaram R; Muralidharan N; Nidanapu RP; Aribandi A; Pradhan SC; Uppugunduri CRS
Genes (Basel); 2020 May; 11(6):. PubMed ID: 32481505
[TBL] [Abstract][Full Text] [Related]
39. NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia.
Chiengthong K; Ittiwut C; Muensri S; Sophonphan J; Sosothikul D; Seksan P; Suppipat K; Suphapeetiporn K; Shotelersuk V
Haematologica; 2016 Jan; 101(1):e24-6. PubMed ID: 26405151
[No Abstract] [Full Text] [Related]
40. Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment.
Kouwenberg TW; van den Bosch BJC; Bierau J; Te Loo DMWM; Coenen MJH; Hagleitner MM
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e94-e97. PubMed ID: 31895215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
